Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2026-05-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司关于董事会换届选举的提示性公告
Board/Management Information Classification · 90% confidence The document is a formal announcement (‘提示性公告’) regarding the upcoming board of directors re-election, detailing the composition, nomination process, candidate qualifications, and procedural steps for electing the 11th board of directors. This is not the actual election results, nor is it a proxy solicitation package or an AGM slide deck. It is a governance/board information announcement, matching the Board/Management Information category.
2026-05-22 Chinese
江苏四环生物股份有限公司关于股票交易异常波动的公告
Regulatory Filings Classification · 75% confidence The document is a regulatory announcement mandated by the Shenzhen Stock Exchange concerning abnormal stock price fluctuations and related disclosures (no undisclosed material information, risk warnings). It does not present financial statements or qualify as an interim report, earnings release, or other specific category. This falls into the general regulatory announcement category.
2026-05-21 Chinese
江苏四环生物股份有限公司关于对深圳证券交易所2025年年报问询函回复的公告
Regulatory Filings Classification · 92% confidence The document is an official announcement by a listed company responding to an inquiry letter from the Shenzhen Stock Exchange regarding its 2025 annual report. It does not itself contain the full annual report but serves as a compliance/regulatory filing to address questions posed by the exchange. Thus it is a general regulatory announcement rather than the report itself, fitting the Regulatory Filings (RNS) category.
2026-05-18 Chinese
江苏四环生物股份有限公司关于公司股票交易撤销退市风险警示暨停复牌的公告
Regulatory Filings Classification · 85% confidence The document is an official market notice concerning the cancellation of a delisting risk warning (“*ST” status), the change of its security abbreviation, and suspension/reopening of trading. It does not contain full financial statements or investor presentation slides, nor is it a formal annual/interim report, earnings release, dividend notice, or capital change. This is a regulatory compliance announcement about trading status and risk warnings, fitting the general Regulatory Filings (RNS) category.
2026-05-18 Chinese
关于江苏四环生物股份有限公司2025年年报问询函相关事项的法律意见书
Regulatory Filings Classification · 85% confidence The document is a lawyer’s legal opinion (“法律意见书”) responding to a Shenzhen Stock Exchange inquiry on the company’s 2025 annual report. It does not itself contain financial statements but provides legal certification and commentary. Under the Certification Rule, such an attestation letter is classified as a general regulatory filing, not the actual annual report or audit report.
2026-05-18 Chinese
中审亚太会计师事务所关于对江苏四环生物股份有限公司2025年年报问询函的回复
Regulatory Filings Classification · 85% confidence The document is a formal response by the company’s auditors to an inquiry letter from the Shenzhen Stock Exchange regarding the 2025 Annual Report. It does not itself present the Annual Report, nor is it a management discussion or audit opinion standalone report. Instead, it is a regulatory reply letter addressing exchange questions on the annual report. It therefore falls under general regulatory filings rather than a primary report type.
2026-05-18 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.